Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (2): 339-342. doi: 10.19723/j.issn.1671-167X.2023.02.020

Previous Articles     Next Articles

Consistency comparison of programmed cell death 1-ligand 1 in different immuno-histochemical staining methods

Dong LI,Ji-ting DI,Yan XIONG*()   

  1. Department of Pathology, Peking University First Hospital, Beijing 100034, China
  • Received:2022-10-12 Online:2023-04-18 Published:2023-04-12
  • Contact: Yan XIONG E-mail:yanxiong1109@163.com

Abstract:

Objective: To compare the consistency of programmed cell death 1-ligand 1 (PD-L1, clone E1L3N, 22C3, SP263) in different immunohistochemical staining methods. Methods: The first step was to select the optimal process: The PD-L1(clone E1L3N) antibody recommended process, self-built process ①, self-built process ② and self-built process ③ were used to perform immunohistochemical staining in 5 cases of tonsil tissue. The quality of all slides was scored by expert pathologists (0-6 points). The process with the highest score was selected. The second step was to compare the consistency between the optimal procedure and the two standard procedures. Thirty-two cases of lung non-small cell carcinoma diagnosed by pathology in Peking University First Hospital in the past two years were randomly selected. The 32 cases were stained in parallel with the SP263 and 22C3 standard procedures, and all stained slides were scored by specialized pathologists for tumor proportion score (TPS). The scoring results were grouped according to < 1%, ≥1% to < 10%, ≥10% to < 50%, and ≥50%. The consistency of PD-L1 detection antibody clone E1L3N and 22C3, E1L3N and SP263 staining results was analyzed. Results: Tonsil stained slides scores (0-6 points) were as follows: The recommended protocol was 5, 5, 5, 5 and 5. The self-built process ① was 5, 6, 6, 5 and 6. The self-built process ② was 4, 4, 4, 4 and 4.The self-built process ③ was 3, 3, 3, 3 and 3. The self-built process ① was the best with the highest score. The TPSs of 32 non small cell lung carcinoma (NSCLC) cases were as follows: Of self-built process ①, 6 cases were lower than 1%, 5 cases were from 1% to 10%, 10 cases were from 10% to 50%, and 11 cases were higher than 50%; of 22C3 standard procedure, 5 cases were lower than 1%, 3 cases were from 1% to 10%, 13 cases were from 10% to 50%, 11 cases were higher than 50%; of SP263 standard procedure, 7 cases were lower than 1%, 4 cases were from 1% to 10%, 11 cases were from 10% to 50%, 10 cases were higher than 50%. The results of the consistency test were as follows: The κ value for self-built process ① and 22C3 standard procedure was 0.736 (P < 0.001), the agreement was good; the κ value for self-built process ① and SP263 standard procedure was 0.914 (P < 0.001), the agreement was very good. Conclusion: The immunostaining using PD-L1(E1L3N) with validated self-built staining protocol ① by Ventana Benchmark GX platform can obtain high quality of slides, and the TPSs based on these slides are in good agreement with 22C3 and SP263 standard procedures.

Key words: Non small cell lung carcinoma, Programmed cell death 1-ligand 1, Colne E1L3N, Immunohistochemistr

CLC Number: 

  • R365

Figure 1

Expression of PD-L1 in tonsil detected by IHC using antibody of E1L3N A, B, crypt epithelium and lymphatic follicles were stained by the amoydiagnostics-recommended protocol(IHC ×200); C, D, crypt epithelium and lymphatic follicles were stained by the self-built protocol ① (IHC ×200); E, F, crypt epithelium and lymphatic follicles were stained by the self-built protocol ② (IHC ×200); G, H, crypt epithelium and lymphatic follicles were stained by the self-built protocol ③ (IHC ×200).PD-L1, programmed cell death 1-ligand 1; IHC, immunohistochemistry."

Figure 2

Expression of PD-L1 in non small cell lung carcinoma detected by IHC using antibody of E1L3N, SP263 and 22C3 A, IHC staining was done by PD-L1(E1L3N, IHC ×100); B, IHC staining was done by PD-L1(SP263, IHC ×100); C, IHC staining was done by PD-L1(22C3, IHC ×100). PD-L1, programmed cell death 1-ligand 1; IHC, immunohistochemistry."

1 Hu-Lieskovan S , Bhaumik S , Dhodapkar K , et al. SITC cancer immunotherapy resource document: A compass in the land of biomarker discovery[J]. J Immunother Cancer, 2020, 8 (2): e000705.
doi: 10.1136/jitc-2020-000705
2 Parra ER , Villalobos P , Mino B , et al. Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1(PD-L1) on non small cell lung carcinoma[J]. Appl immunohistochem mol morphol, 2018, 26 (2): 83- 93.
doi: 10.1097/PAI.0000000000000531
3 Scorer P , Scott M , Lawson N , et al. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay[J]. Diagn Pathol, 2018, 13 (1): 47.
doi: 10.1186/s13000-018-0725-9
4 Kim SY , Kim TE , Park CK , et al. Comprehensive comparison of 22C3 and SP263 PD-L1 expression in non small cell lung cancer using routine clinical and conditioned archives[J]. Cancers (Basel), 2022, 14 (13): 3138.
doi: 10.3390/cancers14133138
5 Song L , Zeng L , Yan H , et al. Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non small cell lung cancer[J]. Commun Med (Lond), 2022, 2 (1): 137.
6 Lawson NL , Dix CI , Scorer PW , et al. Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies[J]. Mod Pathol, 2020, 33 (4): 518- 530.
doi: 10.1038/s41379-019-0372-z
7 Keppens C , Dequeker EM , Pauwels P , et al. PD-L1 immunohistochemistry in non small cell lung cancer: Unraveling differences in staining concordance and interpretation[J]. Virchows Arch, 2021, 478 (5): 827- 839.
doi: 10.1007/s00428-020-02976-5
8 Xu H , Dong X , Zhao H , et al. Clinical evaluation of a laboratory-developed test using clone E1L3N for the detection of PD-L1 expression status in non small cell lung cancer[J]. J Clin Lab Anal, 2021, 35 (3): e23696.
9 Ilie M , Khambata-Ford S , Copie-Bergman C , et al. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms[J]. PLoS One, 2017, 12 (8): e0183023.
doi: 10.1371/journal.pone.0183023
10 Schalper KA , Daniel CH , Joseph M , et al. Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer[J]. J Immunother Cancer, 2015, 3 (2): 415.
11 McLaughlin J , Han G , Schalper KA , et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non small cell lung cancer[J]. JAMA Oncol, 2016, 2 (1): 46- 54.
doi: 10.1001/jamaoncol.2015.3638
[1] Yan XIONG,Bo ZHANG,Li-gong NIE,Shi-kai WU,Hu ZHAO,Dong LI,Ji-ting DI. Thoracic SMARCA4-deficient undifferentiated tumor-pathological diagnosis and combined immune checkpoint inhibitor treatment [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 351-356.
[2] YU Yan-fei,HE Shi-ming,WU Yu-cai,XIONG Sheng-wei,SHEN Qi,LI Yan-yan,YANG Feng,HE Qun,LI Xue-song. Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 640-646.
[3] CHI Yan-ting,ZHANG Yan-ping,ZHANG Qiu-lu,LIU Cui-ling,LI bin-bin. Clinicopathological analysis of mucosa associated lymphoid tissue lymphoma secondary to Sjögren’s syndrome in salivary gland [J]. Journal of Peking University (Health Sciences), 2021, 53(1): 40-45.
[4] Ru MA,Xin-bao LI,Feng-cai YAN,Yu-lin LIN,Yan LI. Clinical evaluation of tumor-stroma ratio in pseudomyxoma peritonei from the appendix [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 240-246.
[5] Xiao-peng ZHANG,Wei-yu ZHANG,Fei HUO,Hao HU,Qi WANG,Ke-xin XU. Outcome of surgical management and pathogenesis of female primary bladder neck obstruction [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1052-1055.
[6] Chun-feng ZHANG,Yun LIU,Min LU,Xiao-juan DU. Expression of hUTP14a in non-small cell lung cancer [J]. Journal of Peking University(Health Sciences), 2019, 51(1): 145-150.
[7] Lei LIU,Li-hua WANG,Yu-bo REN,Xiao-song RAO,Shao-min YANG. Clinicopathological analysis of aggressive angiomyxoma of soft tissue in abdomino-pelvic cavity [J]. Journal of Peking University(Health Sciences), 2018, 50(6): 1098-1101.
[8] MEI Fang, ZHAO Ting-ting, GAO Fei, ZHENG Jie. A rare pulmonary benign bi-phasic tumor: a case report of pulmonary adenofibroma and literature review [J]. Journal of Peking University(Health Sciences), 2017, 49(6): 1076-1080.
[9] LIU Chang, CUI Li-gang, WANG Hong-lei. Renal Ewing’s sarcoma/primitive neuroectodermal tumor: a case report and literature review [J]. Journal of Peking University(Health Sciences), 2017, 49(5): 919-923.
[10] XI Chen-guang, FAN Yu, YANG Xin-yu, LIU Li-bo, WANG Jing-hua, HU Shuai, LI Yan-yan, HE Qun. Clinicopathological features and differential diagnosis of metanephric adenoma: a report of sixteen cases [J]. Journal of Peking University(Health Sciences), 2016, 48(4): 598-602.
[11] SI Jing-wen, WANG Li, BA Xiao-jun, ZHANG Xu, DONG Ying, ZHANG Ji-xin, LI Wen-ting, LI Ting. Clinicopathological screening of Lynch syndrome: a report of 2 cases and literature review [J]. Journal of Peking University(Health Sciences), 2015, 47(5): 858-864.
[12] GONG Bei, HU Hui-Hui, ZHANG Man. Expression of apolipoprotein A-Ⅰ in eight histological types of renal neoplasms [J]. Journal of Peking University(Health Sciences), 2015, 47(1): 155-159.
[13] ZHANG Meng-Xue-1, PEI Fei-1△, WANG Tian-Li-2, HAN Xiang-3, YOU Jiang-Feng-1, ZOU Peng-Cheng-1, WANG Yue-Qi-1, LI Xu-Wen-1, LIU Xin-1, ZHONG Gao-Gao-1, LIU Yan-1, WANG Yu-Xiang-1, WANG Hua-1, ZHANG Bo-1. Anaplastic lymphoma kinase fusion gene expression, clinical pathological characteristics and prognosis in 95 Chinese patients with non-small cell lung cancer [J]. Journal of Peking University(Health Sciences), 2014, 46(4): 582-588.
[14] MA Rui-qiong, CHENG Hong-yan, YE Xue, CHEN Jun, CUI Heng, WEI Li-hui, CHANG Xiao-hong. Expression and significance of tumor necrosis factor receptor associated protein 1 in epithelial ovarian cancer [J]. Journal of Peking University(Health Sciences), 2014, 46(1): 120-124.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2007, 39(5): 507 -510 .
[2] . [J]. Journal of Peking University(Health Sciences), 2000, 32(4): 300 .
[3] . [J]. Journal of Peking University(Health Sciences), 2008, 40(2): 146 -150 .
[4] . [J]. Journal of Peking University(Health Sciences), 2008, 40(4): 369 -373 .
[5] . [J]. Journal of Peking University(Health Sciences), 2010, 42(2): 126 -130 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[7] . [J]. Journal of Peking University(Health Sciences), 2001, 33(2): 181 -182 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(6): 663 -665 .
[9] . [J]. Journal of Peking University(Health Sciences), 2008, 40(1): 39 -42 .
[10] . [J]. Journal of Peking University(Health Sciences), 2010, 42(6): 739 -745 .